Evidence map›Paper›PMID 39737964›Full record

ArticleNature communications2024

Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3

Stefan Wolf, Matiar Madanchi, Patrick Turko, Maija Hollmén, Sonia Tugues, Julia von Atzigen, Pietro Giovanoli, Reinhard Dummer, Nicole Lindenblatt, Cornelia Halin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Keratinocytes: A key player in skin immunity and their emerging roles in secondary lymphedema.JID innovations : skin science from molecules to population health · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stefan WolfDivision of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Matiar MadanchiDivision of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-8396-3977
Patrick TurkoDivision of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-3695-8264
Maija HollménMediCity Research Laboratory, University of Turku, Turku, Finland.ORCID 0000-0002-3250-7653
Sonia TuguesInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Julia von AtzigenDivision of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Pietro GiovanoliDivision of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Reinhard DummerDivision of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-2279-6906
Nicole LindenblattDivision of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Cornelia HalinInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-7899-2850
Michael DetmarInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-5351-5054
Mitchell LevesqueDivision of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-5902-9420
Epameinondas GousopoulosDivision of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. epameinondas.gousopoulos@usz.ch.ORCID 0000-0002-5171-8237

Funding

Academy of Finland (Suomen Akatemia) 316340Novartis Stiftung für Medizinisch-Biologische Forschung (Novartis Foundation for Medical-Biological Research) 22A038
6 · The paper itself

Abstract

Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4

Indexed as

CTLA-4 AntigenForkhead Transcription FactorsLymphedemaMelanomaT-Lymphocytes, RegulatoryAnimalsDisease Models, AnimalFemaleHumansInterleukin-2 Receptor alpha SubunitMaleMiceMice, Inbred C57BLMiddle AgedRetrospective StudiesCTLA-4 AntigenCTLA4 protein, humanForkhead Transcription FactorsFOXP3 protein, humanFoxp3 protein, mouseInterleukin-2 Receptor alpha Subunit

Identifiers

PMID39737964
PMCPMC11686037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.